In two cohorts we found that VR tau‐PET‐negative AD patients were older and had less cognitive impairment, slower cognitive decline, and less hippocampal atrophy compared to tau‐PET‐positive AD patients. The gene discussed is MAPT; the disease is Alzheimer disease.